| Literature DB >> 30463589 |
Eli Ben-Chetrit1, Yonit Wiener-Well1, Emil Lesho2, Puah Kopuit1, Chaya Broyer3, Liora Bier1, Marc V Assous4, Shmuel Benenson5, Matan J Cohen6,7, Patrick T McGann8, Erik Snesrud8, Phillip D Levin9.
Abstract
BACKGROUND: Following a fatal intensive care unit (ICU) outbreak of carbapenem-resistant Acinetobacter baumanii (CRAB) in 2015, an aggressive infection control intervention was instituted. We outline the intervention and long-term changes in the incidence and prevalence of CRAB.Entities:
Keywords: Acinetobacter baumannii; ICU; Infection control; Outbreak
Mesh:
Substances:
Year: 2018 PMID: 30463589 PMCID: PMC6249923 DOI: 10.1186/s13054-018-2247-y
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Fig. 1“Virtual walls” (thick red lines) in the open-plan intensive care unit
Demographics and Acinetobacter baumanii prevalence in the intensive care unit and hospital before and after intervention (cases per 1000 admissions)
| Before intervention (period 1) | One year postintervention (period 2) | Two years postintervention (period 3) | |
|---|---|---|---|
| ICU admissions ( | 513 | 516 | 537 |
| Age (years) | 61 ± 20.2 | 50 ± 21.7 | 59 ± 21.2 |
| Gender (male) | 277 (54%) | 300 (58.1%) | 306 (57%) |
| APACHE II score | 18.3 ± 8.1 | 18.4 ± 8.1 | 18.3 ± 8.0 |
| Median ICU length of stay (days) | 3 (2–6) | 3 (2–7) | 3 (2–6) |
| ICU mortality | 58 (11.3%) | 52 (10%) | 50 (9%) |
| CRAB patients | |||
| CRAB ICU acquisitiona | 54.6 ( | 1.9 (n = 1)b | 5.6 ( |
| CRAB carriers discharged alive from ICU to hospital wardsa | 58.5 ( | 1.9 (n = 1)b | 7.4 ( |
| CRAB ICU admission prevalencea | 56.5 ( | 5.8 (n = 3)b | 13.0 ( |
| Median ICU length of stay (days) | 13 (5–22) | 7 (3–28)c | |
| Median time from ICU admission until CRAB acquisition (days) | 7 (4–11) | 4 (3–32)c | |
| CRAB hospital mortality | 31/57 (54%) | 4/4 (100%) | 6/10 (60%) |
| Medical and surgical wards | |||
| Admissions ( | 39,444 | 41,006 | 44,113 |
| Hospital wards CRAB prevalencea (clinical cultures) | 4.4 ( | 2.4 ( | 2.5 ( |
Abbreviations: APACHE II Acute Physiology and Chronic Health Evaluation II, CRAB Carbapenem-resistant Acinetobacter baumanii, ICU Intensive care unit
aCases/1000 admissions
bp < 0.001 for comparison with preintervention period
cOne and two years postintervention combined owing to small numbers, p = ns compared to preintervention period
Fig. 2Carbapenem-resistant Acinetobacter baumanii daily prevalence in the intensive care unit (red bars) and in the medical and surgical departments (blue bars). The vertical line represents the time point of intervention
Fig. 3Colistin, piperacillin-tazobactam, and meropenem consumption (defined daily dose/100 bed days) before and after intervention in the intensive care unit (left panel) and in the medical and surgical departments (right panel). *p < 0.05 for comparison with preintervention period
Fig. 4MLST (Multilocus Sequence Typing) cluster analysis and single-nucleotide polymorphism differences between carbapenem-resistant Acinetobacter baumanii blood isolates